With all due respect, Richard, you're completely wrong on that. I owned the company from almost the IPO through the May run and have ben plugged into those close to senior management the entire time. I have personally spoken to the Med Research Director on numerous occasions. BMY was, in fact, angry that ENMD would not do a deal on endo after Folkman's work showed that there was synergy between angio and endo in the last round of animal tests in Boston. BMY felt that it had been "left on the beach" with the angio license. It is true that in the angio deal BMY acquired a right of first refusal on intellectual property rights acquired by ENMD from Childrens (and elsewhere) relating to anti-angiogensis technologies in general, but such a right is not an option to acquire - it the right to trump a competitor's bid if, and only if, the grantor of the right decides to sell. ENMD chose not to sell. Even though there were multiple major pharms bidding. All of this noise has, however, been lost in the more recent concerns about NCI's worries, ENMD's interminable delays in commencing clinical trials (suggesting maejor difficulties in production on the scale required for clinicals), and the scientific community's inability to replicate the results.
Please do your homework before accusing me of posting bullsh*t here. You are marginally informed about these issues. At best.
BTW, ENMD if 13.5 by 14 in instinet as of this post.
John |
